FDA Panel Puts PI3K Inhibitors for Blood Cancers on Notice

(MedPage Today) -- Future FDA approvals of four existing PI3K inhibitors for hematologic malignancies should have supporting survival data from randomized clinical trials, according to an advisory committee.
By a 16-0 vote, with one abstention...